Integrated strategy needed to achieve 'TB Mukt Bharat'
Department of Biotechnology is going to play an important part in the integrated holistic healthcare approach against elimination of Tuberculosis
Department of Biotechnology is going to play an important part in the integrated holistic healthcare approach against elimination of Tuberculosis
FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients
It will help upgrade the infrastructure and technologies of the country's biopharmaceuticals and in-vitro diagnostic industry
Cell sorting technology supports researchers advancing new therapies
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
Micafungin for Injection had annual sales of US $99 million in the United States according to IQVIA data
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
LifeWell Raises USD 80M from OrbiMed to Build Large Scale Healthcare Delivery Platform with Full stack Diagnostics~
Subscribe To Our Newsletter & Stay Updated